Making Sense of Prognostic Models in Chronic Myelomonocytic Leukemia

Aziz Nazha, Mrinal M Patnaik

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Purpose of Review: To evaluate established prognostic models in chronic myelomonocytic leukemia (CMML) and describe the challenges associated with their application in clinical practice. Recent Findings: CMML is a clonal hematopoietic stem cell disorder with heterogeneous clinical and molecular features. Outcomes of CMML patients can vary from indolent disease with expected survival measured in years versus proliferative subtypes with rapid progression to acute myeloid leukemia and survival measured in months. Several prognostic scoring systems have been developed to risk stratify CMML patients. While all these models are valid, they demonstrate significant predictive heterogeneity. Summary: Significant intra-patient (applying different models in the same patient giving rise to different prognostic results) and intra-model (patients in a similar prognostic group by a given model can be reclassified to different risk groups by other models) heterogeneities exist when applying current CMML prognostic models in the clinic. A personalized prediction approach may open new opportunities in risk stratifying patients with CMML and other myeloid malignancies.

Original languageEnglish (US)
JournalCurrent Hematologic Malignancy Reports
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Leukemia, Myelomonocytic, Chronic
Survival
Hematopoietic Stem Cells
Acute Myeloid Leukemia

Keywords

  • CMML
  • Models
  • Prognosis

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Making Sense of Prognostic Models in Chronic Myelomonocytic Leukemia. / Nazha, Aziz; Patnaik, Mrinal M.

In: Current Hematologic Malignancy Reports, 01.01.2018.

Research output: Contribution to journalArticle

@article{6a88677a572c4423980729682c404ae6,
title = "Making Sense of Prognostic Models in Chronic Myelomonocytic Leukemia",
abstract = "Purpose of Review: To evaluate established prognostic models in chronic myelomonocytic leukemia (CMML) and describe the challenges associated with their application in clinical practice. Recent Findings: CMML is a clonal hematopoietic stem cell disorder with heterogeneous clinical and molecular features. Outcomes of CMML patients can vary from indolent disease with expected survival measured in years versus proliferative subtypes with rapid progression to acute myeloid leukemia and survival measured in months. Several prognostic scoring systems have been developed to risk stratify CMML patients. While all these models are valid, they demonstrate significant predictive heterogeneity. Summary: Significant intra-patient (applying different models in the same patient giving rise to different prognostic results) and intra-model (patients in a similar prognostic group by a given model can be reclassified to different risk groups by other models) heterogeneities exist when applying current CMML prognostic models in the clinic. A personalized prediction approach may open new opportunities in risk stratifying patients with CMML and other myeloid malignancies.",
keywords = "CMML, Models, Prognosis",
author = "Aziz Nazha and Patnaik, {Mrinal M}",
year = "2018",
month = "1",
day = "1",
doi = "10.1007/s11899-018-0465-7",
language = "English (US)",
journal = "Current Hematologic Malignancy Reports",
issn = "1558-8211",
publisher = "Springer Science + Business Media",

}

TY - JOUR

T1 - Making Sense of Prognostic Models in Chronic Myelomonocytic Leukemia

AU - Nazha, Aziz

AU - Patnaik, Mrinal M

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Purpose of Review: To evaluate established prognostic models in chronic myelomonocytic leukemia (CMML) and describe the challenges associated with their application in clinical practice. Recent Findings: CMML is a clonal hematopoietic stem cell disorder with heterogeneous clinical and molecular features. Outcomes of CMML patients can vary from indolent disease with expected survival measured in years versus proliferative subtypes with rapid progression to acute myeloid leukemia and survival measured in months. Several prognostic scoring systems have been developed to risk stratify CMML patients. While all these models are valid, they demonstrate significant predictive heterogeneity. Summary: Significant intra-patient (applying different models in the same patient giving rise to different prognostic results) and intra-model (patients in a similar prognostic group by a given model can be reclassified to different risk groups by other models) heterogeneities exist when applying current CMML prognostic models in the clinic. A personalized prediction approach may open new opportunities in risk stratifying patients with CMML and other myeloid malignancies.

AB - Purpose of Review: To evaluate established prognostic models in chronic myelomonocytic leukemia (CMML) and describe the challenges associated with their application in clinical practice. Recent Findings: CMML is a clonal hematopoietic stem cell disorder with heterogeneous clinical and molecular features. Outcomes of CMML patients can vary from indolent disease with expected survival measured in years versus proliferative subtypes with rapid progression to acute myeloid leukemia and survival measured in months. Several prognostic scoring systems have been developed to risk stratify CMML patients. While all these models are valid, they demonstrate significant predictive heterogeneity. Summary: Significant intra-patient (applying different models in the same patient giving rise to different prognostic results) and intra-model (patients in a similar prognostic group by a given model can be reclassified to different risk groups by other models) heterogeneities exist when applying current CMML prognostic models in the clinic. A personalized prediction approach may open new opportunities in risk stratifying patients with CMML and other myeloid malignancies.

KW - CMML

KW - Models

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=85052158243&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052158243&partnerID=8YFLogxK

U2 - 10.1007/s11899-018-0465-7

DO - 10.1007/s11899-018-0465-7

M3 - Article

C2 - 30066099

AN - SCOPUS:85052158243

JO - Current Hematologic Malignancy Reports

JF - Current Hematologic Malignancy Reports

SN - 1558-8211

ER -